Anaplastic lymphoma kinase (ALK) is a tyrosine kinase associated with Anaplastic Large Cell lymphoma (ALCL) through oncogenic translocations mainly NPM-ALK. Chemotherapy is …

Sep 29, 2023 · In vitro studies utilizing NPM1-ALK and EML4-ALK-based model systems demonstrate that dysregulation of ALK activity via fusion leads to activation of four key …

Jan 29, 2019 · In this study, we tested the fusion oncogene NPM1-ALK dependency on co-chaperone CDC37 by disrupting the interaction between HSP90 and CDC37, using celastrol …

Dec 7, 2017 · We now report the mechanism underlying NPM1-ALK signaling overdose. We find that all generations of ALK TKIs drive NPM1-ALK overexpression as the most frequent …

Silencing SHP-1 in ALK+ ALCL is important as SHP-1 negative regulates NPM-ALK signalling through either the direct or indirect dephosphorylation of NPM-ALK, JAK2, and STAT3 …

May 5, 2018 · Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) fusion genes resulting from the translocation t (2;5) (p23;q35) are present in almost 90% of childhood ALK-positive …

In this study, we examined the significance of FOXM1 in NPM-ALK-positive anaplastic large cell lymphoma (NPM-ALK + ALCL), with a focus on how it interacts with NPM-ALK, which is a key …

Anaplastic lymphoma kinase (ALK) was first identified in 1994 with the discovery that the gene encoding for this kinase was involved in the t(2;5)(p23;q35) chromosomal translocation …

Sep 29, 2023 · NPM1::ALK induces expression of the NAMPT-encoding gene with STAT3 acting as transcriptional activator of the gene. Inhibition of NAMPT affects ALK + ALCL cells …

In this study, we tested the fusion oncogene NPM1-ALK dependency on co-chaperone CDC37 by disrupting the interaction between HSP90 and CDC37, using celastrol as a therapeutic …